

Drug Coverage Decision for B.C. PharmaCare

About PharmaCare

B.C. PharmaCare is a government-funded drug plan. It helps British Columbians with the cost of eligible prescription drugs and specific medical supplies.

Details of Drug Reviewed

Drug	lurasidone
Brand Name	Latuda®
Dosage Forms	40 mg, 80 mg, 120 mg tablets
Manufacturer	Sunovion Pharmaceuticals Canada Inc.
Submission Review	Resubmission
Use Reviewed	Management of the manifestations of schizophrenia
Common Drug Review (CDR)	Yes. CDR recommended to list with criteria. Visit CDR website for more details: http://www.cadth.ca/media/cdr/complete/SR0331_complete_Latuda_Dec-24-13.pdf
Drug Benefit Council (DBC)	DBC met on February 17, 2014. DBC considered various inputs including: the final review completed by the CDR completed on December 20, 2013, which included clinical and pharmacoeconomic evidence review material, Clinical Practice Reviews from two Specialists, Manufacturer comments; responses to Patient Input Questionnaires from 1 patient, 5 caregivers, and 1 patient group, and a Budget Impact Analysis.
Drug Coverage Decision	Non-benefit
Date	September 16, 2014
Reasons	<p>Drug coverage decision is inconsistent with the DBC recommendation.</p> <ul style="list-style-type: none"> • In indirect comparisons, the drug was found to be similar to aripiprazole and ziprasidone in the management of symptoms of schizophrenia, but was less effective than olanzapine and several other comparable drugs. • Changes in body weight resulting from the use of lurasidone was similar to that of aripiprazole and ziprasidone. • Based on clinical considerations and the submitted product price, the drug was not cost effective and did not offer value for money compared to other covered products. • PharmaCare currently covers many safe and effective antipsychotic alternatives which appear to be adequately meeting most patient needs.
Other Information	A previous evaluation of Latuda® by the CDR recommended that the drug not be listed. Visit the CDR website for more details: http://www.cadth.ca/media/cdr/complete/cdr_complete_Latuda_Jan-25-13_e.pdf

The Drug Review Process in B.C.

A manufacturer submits a request to the Ministry of Health (Ministry).

An independent group called the [Drug Benefit Council](#) gives advice to the Ministry. The Council looks at:

- advice from a national group called the Common Drug Review
- whether the drug is safe and effective
- whether it is a good value for the people of B.C. and the drugs cost
- the ethics of covering or not covering the drug
- input from physicians, patients, caregivers, patient groups and drug submission sponsors

The Ministry makes a decision based on many factors, including:

- advice from the Council
- drugs used to treat similar medical conditions that B.C. PharmaCare already covers
- the overall cost of covering the drug

For more information about the B.C. Drug Review Process, please visit
<http://www.health.gov.bc.ca/pharmacare/outgoing/drugrevproc2.pdf>.

To find out more about the Pharmaceutical Services Division and the PharmaCare program, visit
www.health.gov.bc.ca/pharmacare.

This document is intended for information only.

It does not take the place of advice from a physician or other qualified health care provider.